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Abstract: Methylphenidate is a psychostimulant that inhibits the neuronal dopamine transporter. In addition, methylphe-
nidate has the intriguing ability to provide neuroprotection from the neurotoxic effects of methamphetamine and perhaps 
also Parkinson’s disease; both of which may likely involve the abnormal accumulation of cytoplasmic dopamine inside 
dopaminergic neurons and the resulting formation of dopamine-associated reactive oxygen species. As delineated in this 
review, the neuroprotective effects of methylphenidate are due, at least in part, to its ability to attenuate or prevent this ab-
normal cytoplasmic dopamine accumulation through several possible neuropharmacological mechanisms. These may in-
clude 1) direct interactions between methylphenidate and the neuronal dopamine transporter which may attenuate or pre-
vent the entry of methamphetamine into dopaminergic neurons and may also decrease the synthesis of cytoplasmic dopa-
mine through a D2 receptor-mediated signal cascade process, and 2) indirect effects upon the functioning of the vesicular 
monoamine transporter-2 which may increase vesicular dopamine sequestration through both vesicle trafficking and the 
kinetic upregulation of the vesicular monoamine transporter-2 protein. Understanding these neuropharmacological 
mechanisms of methylphenidate neuroprotection may provide important insights into the physiologic regulation of dopa-
minergic systems as well as the pathophysiology of a variety of disorders involving abnormal dopamine disposition rang-
ing from substance abuse to neurodegenerative diseases such as Parkinson’s disease.  
Key Words: Dopamine, dopamine transporter, methamphetamine, methylphenidate, neuroprotection, neurotoxicity, Parkin-
son’s disease, vesicular monoamine transperter-2. 
INTRODUCTION 
  Methylphenidate (MPD) is a ritalinic acid psychostimu-
lant as shown in Fig. (1). It was first synthesized in 1944 
[40] and is sold under several brand names including Ritalin 
and Concerta. MPD is clinically effective in treating both 
childhood and adult attention-deficit hyperactivity disorder 
as well as narcolepsy [7, 18, 35, 36, 53, 55]. The use of MPD 
has also been studied and advocated for weaning patients 
from mechanical ventilation [23], for treating giggle inconti-
nence [50], and to ameliorate the psychological distress re-
lated to both cancer [11, 60] and human immunodeficiency 
virus infection [12, 76].  
  In the brain, MPD alters the transport of dopamine (DA) 
across the synaptic plasmalemmal membrane by binding 
with high affinity to, and thereby competitively inhibiting, 
the neuronal DA transporter (DAT) [20, 48, 49, 75]. At 
therapeutic doses of 0.3-0.6 mg/kg, orally administered MPD 
may actually bind to and occupy more than half of the DAT 
in the human brain [63]. By inhibiting the DAT, MPD in-
creases extracellular DA concentrations in the brain [55, 61] 
resulting in a prolonged and/or intensified DA postsynaptic 
signal. This DAT inhibition and change in the signal timing 
of DA may, at least in part, mediate the behavioral and lo-
comotor effects of MPD [41, 49]. Additionally, MPD binds 
to and inhibits the neuronal norepinephrine transporter but  
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Fig. (1). Structures of MPD and the cocaine analog, CFT. The 
dashed box indicates the superposition of the atomic sequence from 
the anime nitrogen through the ester group in 3-dimensional space.
has very limited affinity for the serotonin transporter [4, 32]. 
MPD also binds to both muscarinic and serotonin receptors 
in the brain [32].  
  MPD has the intriguing ability to protect against meth-
amphetamine (METH) neurotoxicity. This is evidenced by 
findings that MPD provides complete protection against 
METH-induced decreases in DA transport when rat striatal 
synaptosomes are incubated in vitro with both METH and 
MPD [25]. Additionally, in vivo MPD post-treatment pre-
vents METH-induced persistent decreases in striatal DA 
levels,vesicularDA transport, binding of the vesicular mono-
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nazine (DHTBZ), and vesicular DA content in a rat model of 
METH neurotoxicity [46]. In dopaminergic neurons, METH 
is thought to produce this neurotoxicity by causing excess 
cytoplasmic DA accumulation which, in turn, increases the 
formation of DA-associated reactive oxygen species that 
may overwhelm cellular antioxidant systems [3, 8, 13, 17, 
66, 69].  
  Abnormal cytoplasmic DA accumulation may also con-
tribute to the development of Parkinson’s disease [5, 22], 
suggesting the possibility that MPD may be neuroprotective 
in this disease state as well since MPD treatment has been 
shown to improve motor function in human Parkinson’s pa-
tients [9]. Additionally, MPD provides protection from the 
behavioral and neurochemical effects of 6-hydroxydopamine 
in an animal model of Parkinson’s disease [14]. As detailed 
below, these neuroprotective effects of MPD may be due, at 
least in part, to its ability to attenuate or prevent abnormal 
cytoplasmic DA accumulation in dopaminergic neurons by 
modulating the activity of the DAT and the VMAT-2 
through several neuropharmacological mechanisms.  
MPD NEUROPROTECTION: DIRECT ACTIONS AT 
THE DAT 
  The DAT is a plasmalemmal membrane-spanning protein 
that functions to transport extracellular DA back into the 
cytoplasm of pre-synaptic dopaminergic neurons. As dis-
cussed above, MPD is a DAT inhibitor that competitively 
binds to a single site on the DAT [48, 49, 75]. MPD shares a 
DAT binding pharmacophore with cocaine analogs and the 
sequence of atoms from the amine nitrogen through the ester 
group of MPD (see Fig. 1) is superimposed in 3-dimensional 
space with this same atomic sequence in the cocaine analog, 
CFT [15]. There are three important types of DAT binding 
interactions in this shared pharmacophore: a hydrogen bond 
to the amine nitrogen, one or two hydrogen bonds with the 
ester group, and hydrophobic binding interactions with the 
non-polar phenyl ring [6]. The hydrogen bonding interac-
tions with the ester group involve arginine residues on the 
DAT [64, 70, 71]. The phenyl ring fits into a hydrophobic 
binding pocket on the DAT made up of several amino acid 
residues. The hydrogen bonding interactions are very spe-
cific whereas the hydrophobic binding pocket can accept a 
variety of atomic geometries among various DAT inhibitors. 
The phenyl rings of MPD and the cocaine analogs may thus 
fit into the same hydrophobic pocket on the DAT despite 
their differences in molecular orientation. This is supported 
by findings that MPD, cocaine, and cocaine analogs do in-
deed share the same binding site on the DAT [48, 54, 75].  
  Through these direct binding interactions with the DAT, 
MPD may exert its neuroprotective effects through at least 
two possible neuropharmacological mechanisms. In the first 
possible mechanism, MPD may inhibit the DAT and thereby 
possibly attenuate or prevent METH from gaining entry into 
the neuron and causing DA to efflux from the vesicles. This, 
in turn, may prevent the METH-induced accumulation of 
excess cytoplasmic DA and the resulting formation of DA-
associated reactive oxygen species. In support of this possi-
ble mechanism, DAT-knockout mice are resistant to the neu-
rotoxicity produced by multiple METH administrations [16]. 
Additionally, the DAT inhibitors amfonelic acid, mazindol, 
bupropion, and benztropine block or attenuate the neurotoxic 
effects of METH in rat striatum [31]. These authors con-
cluded that “an intact and functional DA uptake site is neces-
sary for the development of METH-induced long-term DA 
depletions.” MPD can also prevent the neurotoxic effects of 
1-methyl-4-phenylpyridinium (MPP
+) in both human embry-
onic kidney 293 cells expressing the human DAT and in rat 
embryonic mesencephalic cultures by blocking the DAT 
[30].  
  In order for this proposed neuropharmacological mecha-
nism of MPD neuroprotection to be valid, METH must be 
transported by the DAT and not diffuse passively across the 
plasmalemmal membrane. Evidence supporting this assump-
tion can be obtained from empirical calculation. METH has a 
pKa of 10.1 [1, 42] and, depending upon the pH, can exist in 
either a neutral uncharged form or a cationic form as shown 
in Fig. (2). The relative abundance of neutral and cationic 
forms is governed by the Henderson-Hasselbalch equation of 
pH = pKa + log ([neutral]/[cation]). Using this equation and 
the pKa of METH, approximately 0.2% of METH exists in 
the neutral uncharged form at a physiological pH of 7.4. The 
neutral uncharged form of METH is lipophilic with a log P
value of 2.10 while the cationic form is very unlipophilic 
with a log P value of -2.03 [19]. Thus, at physiological pH it 
is possible that only the fraction of METH which exists in 
the neutral uncharged form can passively diffuse across the 
plasmalemmal membrane while the METH which exists in 
the cationic form requires the DAT for transport. This same 
empirical calculation approach has also recently been used to 
calculate the abundance of amphetamine species that can 
diffuse across vesicular membranes [73].  
Fig. (2). Because the amine nitrogen of METH can accept or donate 
a proton, METH exists in an equilibrium between a neutral un-
charged form (shown right) and a positively charged cationic form 
(shown left).
  Experimental evidence also suggests that METH and 
other amphetamines may be transported by the DAT. For 
example, amphetamine accumulation into striatal synapto-
somes is saturable, temperature-dependent, and inhibited by 
MPD [78]. METH elicits "DA-like" transporter-associated 
currents in Xenopus oocytes expressing the human DAT 
[52]. Likewise, the transport of amphetamine into human 
embryonic kidney 293 cells expressing the human DAT is 
Na
+-dependent and produces an inward current [51]. DAT-
mediated accumulation of METH into cultured neuronal 
cells expressing the DAT is directly correlated with tempera-
ture [77]. Finally, amphetamine competes with DA for a 
common binding site on the striatal DAT [74]. Thus, both 
empirical calculation and experimental evidence may sup-
port the assumption that METH, at least at low concentra-
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minergic neurons which may support the first possible 
mechanism of MPD neuroprotection.  
  However, it should be noted that at higher METH con-
centrations there may be a sufficient quantity of the neutral 
uncharged form of METH to diffuse across the plasmalem-
mal membrane and exert biological effects even though the 
neutral uncharged form is not the predominant species in 
terms of relative abundance. For example, 10 @M METH can 
enter nerve terminals and deplete vesicular DA stores in 
brain slices prepared from mice lacking the DAT [24]. Addi-
tionally, Liang and Rutledge [28] proposed a model of am-
phetamine-induced neuronal DA release in which low doses 
of amphetamine are transported by the DAT while am-
phetamine diffuses across the plasmalemmal membrane at 
higher doses.  
  MPD may also provide neuroprotection via a second pos-
sible neuropharmacological mechanism involving direct in-
teractions with the DAT. In this possible mechanism, MPD 
binding to the DAT may inhibit the transport of DA into 
dopaminergic neurons. This may increase extracellular DA 
concentrations which, in turn, may increase D2 receptor ac-
tivation. Increased D2 receptor activation may then decrease 
tyrosine hydroxylase activity and thereby decreases cyto-
plasmic DA synthesis. The end result of this D2 receptor-
mediated cascade of events may be a reduction in both the 
accumulation of cytoplasmic DA and the production of DA-
associated reactive oxygen species. In support of this second 
possible neuropharmacological mechanism, D2 receptor ac-
tivation has been shown to inhibit tyrosine hydroxylase ac-
tivity and DA synthesis in a mouse mesencephalic cell line 
[39] and to also inhibit DA synthesis in striatal synapto-
somes [57]. Additionally, in vivo MPD administration has 
been shown to decrease DA synthesis in rats [38]. However, 
it should be noted that D2 receptor activation may also in-
creases DAT-mediated transport of DA into the cytoplasm 
by increasing DAT cell surface expression [33, 34] which 
may act to attenuate the possible neuroprotective effects of 
this proposed mechanism.  
MPD NEUROPROTECTION: INDIRECT ACTIONS 
ON THE VMAT-2 
  The VMAT-2 is a vesicular membrane-spanning protein 
that functions to transport the cytoplasmic DA inside of neu-
rons into vesicles for storage and subsequent release. The 
VMAT-2 is thus an important regulator of both cytoplasmic 
DA levels and dopaminergic function. Neuronal VMAT-2-
containing vesicles may be classified as either cytoplasmic 
vesicles (i.e., those vesicles that do not co-fractionate with 
synaptosomal membranes after the osmotic lysis of striatal 
synaptosomes) or membrane-associated vesicles (i.e., those 
vesicles that do co-fractionate with synaptosomal mem-
branes after osmotic lysis) [65]. DA transport into cytoplas-
mic vesicles follows Michaelis-Menten kinetics while DA 
transport into membrane-associated vesicles has large posi-
tive substrate cooperativity (i.e., kinetics that are different 
from Michaelis-Menten kinetics) [65, 68]. The membrane-
associated vesicles also have a large DA sequestration capac-
ity and may therefore function as a reserve sequestration 
capacity or “DA sink” to prevent cytoplasmic DA from ris-
ing to aberrant levels [65].  
Synaptic vesicles may coexist in differing functional 
states or pools. These include the readily releasable vesicles 
that are docked at the plasma membrane awaiting exocytosis, 
the recycling vesicles that are undergoing reformation and 
recycling following exocytosis, and the reserve vesicles that 
are not immediately involved in exocytosis and are at a more 
distant location further away from the membrane [44, 45]. It 
has been hypothesized that “synaptic vesicles released by 
osmoticlysis from isolated synaptosomes presumably largely 
correspond to the reserve pool” [37] and thus the cytoplas-
mic vesicles may correspond to the reserve vesicles. Addi-
tionally, “vesicles remaining associated with lysed synapto-
somes may be associated with the presynaptic cytomatrix or 
are docked to the plasma membrane and thus belong to the 
recycling and/or readily releasable pool” [37]. The mem-
brane-associated vesicles may thus correspond to the recy-
cling/ readily releasable vesicles, especially since the mem-
brane-associated vesicle subcellular fraction contains the 
readily releasable vesicle/active zone marker piccolo [65].  
  The disruption of VMAT-2 function in vesicles likely 
contributes to neurotoxicity, since heterozygous VMAT-2 
knock-out mice have increased METH-induced neurotoxicity 
[17]. Additionally, pretreatment with the VMAT-2 inhibitor, 
reserpine, potentiates METH-induced neurotoxicity [56, 72]. 
Finally, METH-induced accumulation of oxygen radicals 
and damage to DA neurites varies inversely with VMAT-2 
expression levels in postnatal ventral midbrain neuronal cul-
tures [27].  
  Multiple high-dose administrations of METH decrease 
vesicular DA transport in cytoplasmic vesicles purified from 
rat striata [2]. METH treatment also decreases both DA 
transport and binding of the VMAT-2 ligand, [
3H]DHTBZ, 
in cytoplasmic vesicles purified from mice striata [21]. How-
ever, there is no significant loss of [
3H]DHTBZ binding in 
whole striatal homogenates prepared from treated mice. 
These and other vesicle trafficking data suggest that multiple 
high-dose METH administrations cause a subcellular redis-
tribution of VMAT-2 containing vesicle out of the cytoplasm 
such that fewer VMAT-2, and presumably associated cyto-
plasmic vesicles, are available to sequester DA [43, 46, 59].  
  MPD and lobeline post-treatments that reverse these 
METH-induced alterations in VMAT-2 redistribution or 
function also prevent neurotoxicity after multiple high-dose 
METH administrations [10, 46]. The neuroprotective effect 
of lobeline is partly due to the attenuation of METH-induced 
hyperthermia, although lobeline may also attenuate gluta-
mate-induced exitotoxicity after METH administration [10]. 
MPD may exert its neuroprotective effects through at least 
two different possible neuropharmacological mechanisms 
involving indirect actions (as opposed to direct binding in-
teractions with the DAT as discussed above) on the DA se-
questration function of the VMAT-2. The first possible neu-
ropharmacological mechanism involves the cytoplasmic 
vesicles while the second possible mechanism involves the 
membrane-associated vesicles. In the first mechanism, MPD 
may redistribute VMAT-2-containing vesicles within striatal 
dopaminergic nerve terminals away from membranes and 
into the cytoplasm which may result in the movement of 
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activity because of the actions of METH [46, 47]. MPD may 
thus increase vesicular DA sequestration in that region and 
perhaps compensate for any METH-induced cytoplasmic DA 
accumulation. In this way, MPD may reverse or prevent de-
generative processes associated with decreased VMAT-2 
function and aberrant DA storage.  
  This possible mechanism of neuroprotection is supported 
by the experimental findings that MPD increases and de-
creases VMAT-2 immunoreactivity in the cytoplasmic and 
membrane-associated vesicle subcellular fractions, respec-
tively, without altering total synaptosomal VMAT-2 content 
[47]. Binding of [
3H]DHTBZ is affected similarly [47]. The 
trafficking of vesicles away from membranes and into the 
cytoplasm increases DA transport into cytoplasmic vesicles 
by simply increasing the number of VMAT-2 containing 
cytoplasmic vesicles (as opposed to altering the function of 
each individual VMAT-2 protein) [46, 47, 65]. MPD thus 
increases DA transport by increasing both the Vmax of DA 
transport and the density of kinetically active VMAT-2 
without changing the Km, the catalytic rate constant, or the 
rate constant for DA binding to the VMAT-2 [65]. This sug-
gests that the kinetics of DA binding to the VMAT-2 and the 
translocation of DA across the vesicular membrane are unal-
tered [65, 67]. MPD also increases the DA content of puri-
fied vesicles without altering total tissue DA content [46, 65] 
which suggests that MPD redistributes DA within the nerve 
terminals, presumably as a consequence of the redistribution 
of vesicles. These MPD-induced vesicle trafficking effects 
are D2 receptor-mediated as the D2 receptor antagonist, eti-
clopride, attenuates or blocks these effects and the D2 recep-
tor agonist, quinpirole, mimics the effects of MPD on cyto-
plasmic vesicles [47, 58]. This suggests that these trafficking 
effects are likely due to the ability of MPD to increase ex-
tracellular DA concentrations by blocking the DAT [26, 62].  
  In the second possible neuropharmacological mechanism 
of neuroprotection, MPD actually alters the functioning of 
VMAT-2 in the membrane-associated vesicles to transport 
more DA. This mechanism is supported by the findings that, 
in addition to redistributing vesicles away from membranes 
and into the cytoplasm, MPD also increases vesicular DA 
Fig. (3). The neuroprotective effects of MPD are caused by at least four possible mechanisms: two involving direct interactions with the
DAT and two involving indirect effects upon the VMAT-2. These mechanisms, shown in Panel A (no MPD) and Panel B (with MPD), may
decrease DAT-mediated METH transport and cytoplasmic DA synthesis while also increasing DA transport into cytoplasmic and membrane-
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sequestration into the remaining membrane-associated vesi-
cles [65]. MPD thus kinetically upregulates the VMAT-2 
protein itself in the remaining vesicles such that a larger 
quantity of DA is transported [65]. By increasing membrane-
associated vesicular DA sequestration in this manner, MPD 
may attenuate or prevent the degenerative processes associ-
ated with METH-induced decreased VMAT-2 function and 
cytoplasmic DA accumulation. Because abnormal cytoplas-
mic DA accumulation also likely contributes to the devel-
opment of Parkinson’s disease [22], the potential of MPD-
induced increases in vesicular DA sequestration (caused by 
vesicle trafficking in the cytoplasmic vesicles and by kinetic 
upregulation of VMAT-2 in the membrane-associated vesi-
cles) to attenuate the disease’s progression merits further 
investigation; as suggested by findings that MPD treatment 
improves motor function in Parkinson’s patients [9].  
  These MPD-induced increases in vesicular DA sequestra-
tion may have several additional interesting functional con-
sequences. The increase in vesicular DA transport increases 
vesicular DA content with no change in whole striatal tissue 
DA content [46, 65]. By increasing vesicular DA transport 
velocities, MPD thus redistributes DA within the striatum 
from the cytoplasm and into the vesicles. As a consequence 
of increased vesicular DA sequestration and DA content, 
MPD also increases the speed and extent of stimulated DA 
release from striatal suspensions [65]. The amount of vesicu-
lar DA content and the speed of neurotransmitter release can 
influence receptor activation [29], and MPD may thus influ-
ence quantal synaptic transmission in the striatum by in-
creasing the rate at which DA receptors are exposed to DA, 
and perhaps the magnitude and/or duration of this effect.  
CONCLUSION 
  The studies reviewed above help us to understand how 
MPD has the ability to provide neuroprotection against 
METH-induced neurotoxicity and perhaps Parkinson’s dis-
ease through possible mechanisms involving direct interac-
tions with the DAT and additional mechanisms involving 
indirect effects upon the VMAT-2. These mechanisms, 
summarized in Fig. (3), attenuate or prevent the abnormal 
accumulation of cytoplasmic DA and the resulting formation 
of potentially neurotoxic DA-associated reactive species. At 
present, it is difficult to quantify the amount that any indi-
vidual mechanism contributes to MPD neuroprotection in
vivo. Further studies investigating the neuropharmacology, 
biochemistry,andmolecularbiology underlying these mecha-
nisms are warranted as these will help to determine the in
vivo contribution of each mechanism. These additional stud-
ies may also provide insight into the physiologic regulation 
of dopaminergic systems as well as the pathophysiology of a 
variety disorders involving abnormal DA disposition ranging 
from substance abuse to neurodegenerative diseases such as 
Parkinson’s disease. Ultimately, this may suggest leads for 
developing related novel and more effective neuropharma-
cologic therapeutic treatment strategies. 
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